NASDAQ$PETS

PetMed Express · Q4 2026 earnings

Q4 2026 earnings · · After market close · Investor relations

Briefing

PetMed Express reported a net loss of $4.1 million on net sales of $42.8 million for its fourth quarter ended March 31, 2026.

Net sales declined 15.6% year-over-year to $42.8 million, primarily due to lower prescription medication sales. The net loss narrowed to $4.1 million from $11.6 million in the prior-year quarter, aided by reduced operating expenses and the absence of a prior-year impairment charge. Adjusted EBITDA was negative $2.8 million versus negative $1.9 million last year.

  • Q4 net sales fell 15.6% to $42.8 million, driven by lower prescription medication revenue.
  • Net loss improved to $4.1 million ($0.19 per share) from $11.6 million ($0.56 per share) year-over-year.
  • Adjusted EBITDA declined to negative $2.8 million from negative $1.9 million in the prior-year quarter.
  • Full-year net sales dropped 21.1% to $179.0 million with a net loss of $57.3 million, including a $26.7 million goodwill impairment.

Headline financials

Total Revenue

$42.8M

Previous: $44M-2.6%
EPS (adj)

-$0.19

No prior period
Net Income

-$4.06M

No prior period
Operating Income

-$5.69M

No prior period
Gross Profit

$13.9M

No prior period
Cash & Equivalents

$21.4M

No prior period
Total Assets

$81.2M

No prior period

Revenue & EPS history

PetMed Express · Revenue · Quarterly

$42.8M

Q4 2026-2.6%vs Q4 2025
Beat estimate in 3 of 14 quarters(21%)
ActualEstimate

Forward guidance

Management highlighted sequential sales improvement and cost-structure reductions while remaining open to future strategic proposals.

Tailwinds

  • Modest sequential quarterly sales increase signals positive momentum
  • Completed initiatives that reduced cost structure
  • Focus on customer retention and B2B expansion via membership and white-label services

Headwinds

  • Board declined two unsolicited acquisition proposals ranging from $4.00 to $4.25 per share

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2026

Historical avgQ4 2026

-0.0%

Avg return

Earnings day

-1.6%

Avg return

5 days after

-0.4%

Avg return

30 days after

42%

27 / 65 earnings

Positive

+40.8%

Q2 2020

Best reaction

-26.4%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-16.4%-21.1%
Q3 2026-3.6%-8.7%-15.5%
Q4 2025+0.0%-4.9%-6.6%
Q2 2026-1.4%-2.7%-8.2%
Q1 2026-1.1%-1.4%-6.9%
Q3 2025-14.8%-20.1%-22.7%
Q2 2025+34.5%+27.2%+35.0%
Q1 2025-11.0%-13.0%-4.5%
Q4 2024-0.7%-1.7%-7.4%
Q3 2024+0.2%-1.2%+8.9%
Q2 2024-26.4%-23.0%-22.6%
Q1 2024-2.8%-6.4%-20.0%
Q4 2023+6.7%+1.0%-6.6%
Q3 2023-11.1%-13.3%-19.6%
Q2 2023-10.5%-4.7%-15.5%
Q1 2023+4.3%+4.2%+0.9%
Q4 2022+6.9%+2.0%+3.0%
Q3 2022+7.2%+7.7%+3.4%
Q2 2022+5.1%+5.1%+5.2%
Q1 2022+7.1%+13.0%+3.2%
Q4 2021+2.8%+0.5%+56.5%
Q3 2021-14.3%-11.1%+3.2%
Q2 2021-2.2%-3.5%-1.9%
Q1 2021-16.0%-23.8%-17.4%
Q4 2020+3.6%-4.0%-7.5%
Q3 2020-11.0%-11.2%+4.0%
Q2 2020+40.8%+32.8%+21.7%
Q1 2020+2.5%-1.5%+5.1%
Q4 2019-9.0%-9.7%-18.9%
Q3 2019-6.2%-3.4%-3.1%
Q2 2019+2.6%+1.1%-9.7%
Q1 2019-13.0%-11.8%-6.4%
Q4 2018-0.9%+1.4%+15.1%
Q3 2018-4.8%-10.2%-12.0%
Q2 2018+4.4%-5.0%+9.0%
Q1 2018+18.6%+19.3%-10.7%
Q4 2017+34.7%+41.2%+48.4%
Q3 2017-5.1%-5.4%-3.6%
Q2 2017-3.2%-4.0%+6.6%
Q1 2017+6.0%+5.8%+3.3%
Q4 2016+2.9%
Q3 2016-4.8%
Q2 2016+2.1%
Q1 2016+0.5%
Q4 2015+2.6%
Q3 2015+14.3%
Q2 2015-3.7%
Q1 2015+5.0%
Q4 2014+1.6%
Q3 2014-12.0%
Q2 2014-10.3%
Q1 2014+12.7%
Q4 2013-0.5%
Q3 2013+7.0%
Q2 2013+6.9%
Q1 2013-16.3%
Q4 2012-5.4%
Q4 2010-5.4%
Q3 2011-0.2%
Q3 2012-0.2%
Q2 2012-0.8%
Q2 2011-0.8%
Q1 2012-0.1%
Q1 2011-0.1%
Q4 2011-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro